SCHEMBL6932241

SCHEMBL6932241

O=C1OC(c2ccc(-c3ccc(Cl)cc3)cc2Cl)(C2CCCCC2)C(O)=C1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 2/20 0.36
ALOX5 P09917 1/20 0.34
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
PGR P06401 1/20 0.33
TDP2 O95551 1/20 0.33
CCR2 P41597 3/20 0.32
CCR1 P32246 2/20 0.32
ALDH1A1 P00352 3/20 0.32
RAB9A P51151 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
ALOX15B O15296 1/20 0.32
ACACB O00763 1/20 0.32
ACACA Q13085 1/20 0.32
CNR1 P21554 1/20 0.32
CNR2 P34972 1/20 0.32
NPC1 O15118 2/20 0.32
CCR5 P51681 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6934430 0.91 AKR1C2 (0.36) PTGER3CCR2CCR1RAB9AACACB
SCHEMBL7968980 0.81 PTGER3 (0.35) PTGER3CCR2CCR1RAB9ANPC1
SCHEMBL6931685 0.75 PGR (0.43) PTGER3ALOX5PGRTDP2ALDH1A1
SCHEMBL7956141 0.73 HSD11B1 (0.37) L3MBTL1
SCHEMBL7968985 0.72 NOTUM (0.39) RAB9ANPC1
SCHEMBL6932901 0.72 PGR (0.41) ALOX5PGRALDH1A1SMN1; SMN2
SCHEMBL6026778 0.70 BACE1 (0.36) RAB9ANPC1
SCHEMBL7968559 0.70 DHFR (0.39) PTGER3SLC6A2SLC6A4SLC6A3ALDH1A1
SCHEMBL6026240 0.69 MCL1 (0.35) SLC6A2SLC6A4SLC6A3ALDH1A1CNR1
SCHEMBL6931613 0.67 AKR1C2 (0.42) PTGER3PGRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 US claimed
EP-1246811-B1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN LTD (GB) 2003-12-03 EP disclosed
US-6613919-B2 Resolution with enantiomerically pure bases such as cinchonidine by forming a salt; also 3,4-dihydroxy-2(5H)-furanones OXIS ISLE OF MAN 2003-09-02 US disclosed
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones OXIS ISLE OF MAN 2003-04-03 US disclosed
EP-1246811-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS Isle of Man, Limited (GB) 2002-10-09 EP disclosed
US-6265436-B1 ANTIINFLAMMATORY AGENTS OXIS THERAPEUTICS INC. 2001-07-24 US disclosed
WO-2001049671-A1 METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES OXIS ISLE OF MAN, LIMITED (US) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065196-A1 Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones ADH1C, SRD5A2, SRD5A1 PTGER3 1547/4885ALOX5 88/4885SLC6A2 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.